Global M&A trends in health industries: 2025 outlook
Health industries dealmakers gear up for a more favourable M&A environment in 2025.
Pharmaceuticals & life sciences publications
35 results
Loading...
The future of care
The healthcare industry is evolving into a dynamic ecosystem. Patients, practitioners and industry players all stand to benefit.
Next in pharma 2025: The future is now
Four strategic bets and a suite of capabilities for the pharma industry to help you determine how your company can create value in the future.
Taiwan health industries
A comprehensive introductory guide to Taiwan’s healthcare system and its biopharma and medical device sectors
SAP S/4HANA for the life sciences supply chain function
SAP S/4HANA and provides the pharma and life sciences industry with advanced applications, analytics and reporting capabilities for supply chain transformation.
Global M&A trends in health industries: 2024 mid-year outlook
M&A strategies in health industries focus on unlocking value and innovation: dealmakers gear up for a busy second half of 2024.
Global M&A trends in health industries: 2024 outlook
Competition for innovative technologies will be fierce as dealmaking headwinds begin to subside, accelerating health industries M&A in 2024.
Putting patients at the centre of quality
How can quality organisations embrace a patient-centric approach to drive value? To find out where the industry stands on ‘patient-centred quality’, we surveyed and assessed biopharmaceutical and medtech companies’ current approach to quality.
Global M&A Trends in Health Industries: 2023 Mid-Year Update
M&A will remain a key transformation tool for health and pharmaceutical companies in the second half of 2023.
GlaxoSmithKline's HR transformation journey
GlaxoSmithKline wanted to future-proof their HR function. PwC and Workday worked in collaboration to address the pain points in an employee life-cycle by optimising Workday functions and implementing ServiceNow to support HR services.
Global M&A Trends in Health Industries: 2023 Outlook
Health industries M&A is set to rebound in 2023, with investors attracted by innovation and growth prospects.
From healthcare to life care: Transforming precision health
Technology and evolving consumer preferences are setting the stage for a transformation in the way that healthcare delivers and creates personal, societal and financial value.
How to develop and commercialise digital health solutions
Our survey explores the top five challenges facing leading pharma and MedTech companies and highlights recommendations on how they can overcome these impediments.
Taking Affiliate Quality into the future
How quality organisations must evolve to be future-ready.
Global M&A Industry Trends in Health Industries: 2022 Outlook
Heightened PE interest and investments are propelling megadeals in 2021
How to make digital health stick
The growth of digital health solutions has accelerated rapidly in the post-COVID era. But while there are plenty of innovative ideas in development, many companies are still struggling to move beyond promising pilots and into production at scale.
Sustainability in manufacturing: Delivering net-positive returns
Sustainability should not be seen as a cost that must be offset somewhere else. Manufacturers can turn sustainability into a value differentiator by focusing on three areas.
How New Zealand’s Whakarongorau Aotearoa is improving equity in healthcare
CEO Andrew Slater describes how the telehealth company has scaled up to meet unprecedented demand while staying true to its mission.
Manufacturing COO Pulse Survey
What does the future of manufacturing look like? In PwC’s COO Pulse Survey, we reveal the plans and priorities of global manufacturing executives.
Global Top Health Industry Issues 2021
In our new report, PwC’s look at four top themes that now affect global healthcare providers, insurers, pharmaceutical and life sciences companies, new entrants and employers.
Building a high-performing pharma organisation in a virtual world
Remote working is here to stay - but with some roles and activities necessitating a physical workplace, what does this mean for the pharma sector?
Empowerment will be at the heart of the new healthcare experience
COVID-19 has highlighted the importance of keeping patients, families, and caregivers informed and connected, and of valuing them as co-creators in building the future of healthcare delivery.
Pfizer’s vaccine machine
CEO Albert Bourla discusses how a company founded in the 19th century is taking on the biggest health challenges of the 21st century.
Future Pharma
New technologies and emerging trends like robotics, artificial intelligence and precision medicine are disrupting the pharmaceutical industry.
Global insights: the COVID-19 response
COVID-19 has upended healthcare around the world. As companies and governments race to produce and distribute vaccines, PwC provides insights for leaders in these challenging times.
Accelerating the health economy of tomorrow
The pandemic edits the DNA of the health system
Mission: ‘patient centricity’
How technology can help achieve personalised care for rare disease patients.
Reimagining healthcare: Telemedicine initiatives for COVID-19
Throughout history, epidemics and pandemics have driven profound changes in economic, social and business structures.
Preparing your life sciences company to go public
The number of life sciences companies raising capital through public offerings has been rising steadily for the past few years.
Social Determinants of Health
Expanding the health ecosystem to encompass where people live, work and play.
Driving the future of health
By 2030, healthcare will be centered on patients empowered to prevent diseases rather than seek treatment.
'Return on experience' in healthcare and pharmaceuticals
PwC’s 10th annual Global Consumer Insights Survey (GCIS) — which gathers the sentiments of more than 21,000 online consumers in 27 territories — shows that in addition to the traditional return on investment (ROI) metrics used to determine a healthcare or pharmaceutical company’s success, we need to introduce another...
IFRS - Issues and solutions for the pharmaceuticals and life sciences industry - 2019 edition
PwC’s insight on how to apply IFRS in common pharmaceuticals and life sciences transactions, including guidance on the new revenue standard, IFRS 15.
How Robots Will Transform the C-Suite
Senior executives need to lead a workforce that seamlessly blends human talent and automation. Visit strategy+business to read more.
New dynamics of the pharmaceutical oncology market
Amid projected growth, the pharmaceutical oncology market is undergoing significant change.
Loading...
Contact us
Global Pharmaceutical and Life Sciences Assurance Leader, PwC Switzerland
Tel: +41 79 5429018
Global Health Industries Tax Leader, PwC United Kingdom
Tel: +44 (0)7793 580784